CTOS 2024: A preclinical assay pipeline to identify and optimize brachyury-targeted therapies in chordoma and other solid tumors

This research poster provides the rationale for drugging Brachyury and highlights CF Lab's capabilities that enable discovery of new Brachyury drugs. Brachyury is not only a diagnostic biomarker but a key driver of chordoma pathogenesis. Functional genomics identified Brachyury (TBXT), a T-box transcription factor, as the most selectively essential gene in chordoma. Groundbreaking research from the Structural Genomics Consortium solved the crystal structure of Brachyury and generated structure-guided small molecule libraries that can bind to Brachyury. Building on these recent efforts, CF Labs developed a suite of pre-clinical assays that combines biophysical and cell-based assays that can identify and characterize new Brachyury drugs.